Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome. A multicentre, retrospective, real-world French study.
Fiche publication
Date publication
avril 2023
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALAC Sophie, Dr NARDIN Charlée
Tous les auteurs :
Beylot-Barry M, Quereux G, Nardin C, Duval-Modeste AB, Dereure O, Dalac-Rat S, Dobos G, Pham-Ledard A, Ram-Wolff C, D'Incan M, Grange F, Braniste V, Bagot M
Lien Pubmed
Résumé
Efficacy and safety of mogamulizumab, a monoclonal antibody directed against C-C chemokine receptor 4, were demonstrated in a previous multinational clinical trial conducted in patients with previously treated cutaneous T-cell lymphoma (CTCL): Sézary syndrome (SS), or Mycosis Fungoides (MF).
Référence
J Eur Acad Dermatol Venereol. 2023 04 27;: